P1438 - Is Aspirin Use Associated With Decreased Incidence, Better Outcomes, and Decreased Cost of Acute Pancreatitis Hospitalizations?

Praneeth Bandaru, MD¹, Arnold Forlemu, MD, MPH¹, Vijay Gayam, MD¹, Vishnu Poojitha Ronda, MBBS, MD², Pavani Reddy Garlapati, MD¹, Enmanuel Then, ³, Hamsika Moparty, MD¹, Raissa Nana Sede Mbakop, MD⁴, Saigopal R. Gujjula, ⁵, Vikash Kumar, MD¹, Denzil Etienne, MD¹, Madhavi Reddy, MD^1
1Brooklyn Hospital Center, Brooklyn, NY; ²Mahatma Gandhi Medical College and Research Institute, Pondicherry, India, Brooklyn, NY; ³Universidad Iberoamericana, Gazcue, Distrito Nacional, Dominican Republic; ⁴Piedmont Athens Regional Medical Center, Athens, GA; ⁵American University of Antigua, Coolidge, Saint John, Antigua and Barbuda

Introduction: Acute pancreatitis is an acute painful abdominal condition with an unpredictable course, that varies in severity and course from patient to patient and is one of most common gastrointestinal causes of hospitalization. In United States alone, acute pancreatitis accounts for health care costs of $ 2.5 billion per year and up to 300,000 admissions per year, with overall mortality although trending down over the years is still at 2%. In this study we aim to study the factors affecting the outcomes ( morality, LOS, total hospital charges ) associated with acute pancreatitis.

Methods: We conducted a nationwide review from 2016 to 2017 using the National Inpatient Sample (NIS) data. NIS is the largest publicly available all-payer inpatient database in the United States with more than seven million hospital stays each year, as a part of the Healthcare Cost and Utilization Project (HCUP). Patients ≥18 years old with acute pancreatitis were identified using the ICD-10-CM codes. Among acute pancreatitis patients, 15,495 of them were taking aspirin. Adjusted odds ratio (OR) and confidence intervals (CI) at 99% were reported.

Results: The number of patients with acute pancreatitis was 180,610, with a mean age of 53.36 years and 51.9% males. Aspirin use was associated with a lower risk for acute pancreatitis (OR 0.70, 0.69-0.71) after adjusting for potential confounders. On subgroup analysis, aspirin use was associated with a lower risk of alcohol induced pancreatitis (OR 0.35, 0.33-0.37). There was no significant association between aspirin use and acute biliary pancreatitis, idiopathic acute pancreatitis, or drug induced acute pancreatitis. On multivariate analysis, aspirin users were significantly less likely to die from acute pancreatitis (OR 0.49, 0.41 – 0.58), had a shorter length of stay, and incurred less charges compared to patients with acute pancreatitis that were not on aspirin.

Discussion: This study results have shown that aspirin usage is associated with significantly lower rates of acute pancreatitis especially for alcohol induced pancreatitis, and aspirin usage is also associated with significantly better outcomes in patients admitted with acute pancreatitis and has reduced the cost of hospitalization. These are animal studies showing the beneficial effects of aspirin in acute pancreatitis, however human studies and well-designed trails are missing and are needed which can potentially change the approach to acute pancreatitis management.


Disclosures:


Praneeth Bandaru, MD¹, Arnold Forlemu, MD, MPH¹, Vijay Gayam, MD¹, Vishnu Poojitha Ronda, MBBS, MD², Pavani Reddy Garlapati, MD¹, Enmanuel Then, ³, Hamsika Moparty, MD¹, Raissa Nana Sede Mbakop, MD⁴, Saigopal R. Gujjula, ⁵, Vikash Kumar, MD¹, Denzil Etienne, MD¹, Madhavi Reddy, MD¹. P1438 - Is Aspirin Use Associated With Decreased Incidence, Better Outcomes, and Decreased Cost of Acute Pancreatitis Hospitalizations?, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.